Exercise to Slow Cardiovascular Ageing Progression

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05775484

Enrollment

450

Registered

2023-03-20

Start date

2023-05-01

Completion date

2050-12-31

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Ageing, Cardiovascular, Exercise

Brief summary

In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.

Detailed description

Participants from each stratum will be randomized to receive either an exercise program intervention or no exercise. At the start and end of study, participants will undergo cardiovascular imaging and metabolic profiling. Investigators will determine if exercise can reverse high-risk metabolic profiles and improve cardiovascular structure and function. Without clear mechanisms to explain cardiovascular ageing nor interventions known to retard cardiovascular ageing, our approach will provide much needed translational evidence to incorporate targeted interventions aimed at reducing cardiovascular disease risk in older populations.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* Age \>=21 years old * Outdoor ambulant

Exclusion criteria

* Wheelchair or bed-bound * Dementia * Residing in sheltered or nursing home * Cancer * Participation in ongoing clinical trials that involve interventional drugs or devices * Aneurysms * Acute infections (in the last six months) * Uncontrolled thyrotoxicosis * Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise * Uncontrolled asthma or chronic lung disease * Restrictive lung disease

Design outcomes

Primary

Measure	Time frame	Description
Metabolite profiles	12 Months	To measure changes in serum metabolite levels among participants pre and post exercise intervention.
Cardiovascular structure and function	12 Months	To measure changes in CV structure and function (diastolic function, arterial stiffness) among participants.

Countries

Singapore

Outcome results